High-Quality Tech Stocks Face Brutal Repricing Amid AI Capex Anxiety

A significant rotation is underway within the technology sector as investors reprice the winners and losers of the AI buildout. Names like Epam, Costar, and Ping Identity, which were priced for flawless execution and secular tailwinds, are down sharply YTD and trading near 52-week lows. Simultaneously, direct AI infrastructure plays (chips, compute, data centers) are rallying hard. This reflects a narrative shift: capital is fleeing from 'nice-to-have' AI-adjacent software and running toward 'must-have' infrastructure and core compute. The Cerebras IPOInitial Public Offering - a company's first public sale of stock. price-range hike to $150-$160 per share (up from $115-$125) and demand surge exemplify this flow.

The fundamental concern underpinning the repricing is capex durability and ROI realization. While cloud giants are spending aggressively on AI infrastructure, questions linger about when that capex translates into revenue growth and margin expansion. Software vendors that depend on data center operators and AI platforms as customers face a revenue timing risk; they may be priced as if AI adoption is imminent, but adoption could lag expectations. Additionally, mega-cap SaaS companies like NOW, CRM, and related names are facing a tougher growth backdrop as SMB customers pull back on discretionary spending amid persistent inflationThe rate at which prices rise across an economy. concerns.

The repricing has also been exacerbated by positioning and technical factors. Semis and memory stocks have run into overbought conditions (RSIRelative Strength Index - momentum oscillator on a 0-100 scale. at 85-90 on weekly timeframes for some), while 'quality' mega-cap software has lagged, inviting shorts and tactical bears to express their view. Nvidia's stock, though not collapsing, has trended sideways for weeks despite earnings euphoria, suggesting profit-taking and rotation flow among institutions. CoreWeave and similar infrastructure picks are being lifted by Nvidia's public endorsement, creating a perception that Nvidia itself has 'moved on' from software enablers.

The counter-narrative is that high-quality SaaS with pricing power will ultimately benefit from AI monetization as enterprises shift budgets from legacy software to AI-native tools. Leerink Partners and other analysts have lifted price targets on healthcare tech names expecting data-driven care to compound margins. The risk, however, is that this repricing could extend further if data center capex moderates or if cloud giants develop in-house alternatives to third-party software.